金斯瑞生物科技(01548.HK)附屬發布兩項研究之最新資料
金斯瑞生物科技(01548.HK)公布,附屬子公司傳奇生物科技在第62屆美國血液學會(「ASH」)年會將分別公布CARTITUDE-1和LEGEND-2兩項研究的最新資料。ASH年會將於2020年12月5日至12月8日通過虛擬會議舉行。
口頭報告期間將展示CARTITUDE-1的某些更新資料,重點介紹靶向B細胞成熟抗原(BCMA)的嵌合抗原受體T細胞(「CAR-T」)療法(西達基奧侖賽,CiltacabtageneAutoleucel;cilta-cel)在治療復發或難治性多發性骨髓瘤的1b/2期臨床研究中的療效和安全性結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.